Skip to nav Skip to content
Jonathan  Strosberg

Jonathan Strosberg, MD

4.8 (188)

Specialty: Medical Oncology

Program: Gastrointestinal Oncology

Language(s): English

  • Overview

    Cancer Focus:
    Neuroendocrine Tumor

    Dr. Jonathan Strosberg is a professor at Moffitt Cancer Center specializing in the management of neuroendocrine malignancies. He is a graduate of Harvard University and Cornell University Medical College and completed his residency and fellowship training programs at Georgetown University Hospital and Moffitt Cancer Center. He leads Moffitt’s Neuroendocrine Tumor Division and Department of Gastrointestinal Oncology Research Program. Dr. Strosberg has published over 150 articles on the diagnosis and management of neuroendocrine malignancies, with first-author publications in the New England Journal of Medicine, Journal of Clinical Oncology, Annals of Oncology, Clinical Cancer Research and other major journals.  He is a recipient of the National Cancer Institute’s Clinical Investigator Team Leadership Award.  He also serves on the board of directors of the North American Neuroendocrine Tumor Society (NANETS), the Neuroendocrine Guidelines Committee of the National Comprehensive Cancer Network (NCCN) and the Neuroendocrine Task Force of the National Cancer Institute (NCI).  

    Education & Training

    Board Certification:

    • Internal Medicine - Medical Oncology


    • H. Lee Moffitt Cancer Center & Research Institute - Medical Oncology & Hematology


    • Georgetown University Hospital - General Internal Medicine

    Medical School:

    • Cornell University Medical College - MD
  • Participating Trials

    Clinical Trial 19943
    Somatostatin receptor expression in poorly-differentiated neuroendocrine carcinomas of the GI tract: analysis using 68Ga-dotatate PET scan
    Condition: Gastrointestinal Tumor
    Status: Open

    Clinical Trial 21383
    A Prospective, Randomized, Controlled, Open-label, Multicenter Trial to Evaluate Efficacy, Safety and Patient-reported Outcomes of Peptide Receptor Radionuclide Therapy (PRRT) with Lutetium (177Lu) Edotreotide compared to Best Standard of Care in Patients with Well-differentiated Aggressive Grade 2 and Grade 3, Somatostatin Receptor-positive (SSTR+), Neuroendocrine Tumors of GastroEnteric or Pancreatic Origin (COMPOSE)
    Condition: Gastrointestinal Tumor
    Intervention: 177Lu-edotreotide (); 5-fluorouracil (); Not Applicable (); Oxaliplatin (); Temodal (Temozolomide); Temozolomide (); Xeloda (capecitabine); capecitabine (); eloxatin (Oxaliplatin); everolimus (RAD001); leucovorin ()
    Status: Open

    Clinical Trial 21664
    Phase 1b/3 z=Global, Randomized, Controlled, Open-Label Trial Comparing Treatment with RYZ101 to Standard of Care (SoC) Therapy in Subjects with Inoperable, Advanced, Somatostatin Receptor Expressing (SSTR+), Well-Differentiated Gastro-Enteropancreatic Neuroendocrine Tumors (GEP-NETs) that have Progressed Following Prior 177Lulabelled Somatostatin Analogue (177Lu-SSA) Therapy (ACTION-1).
    Condition: Gastrointestinal Tumor
    Intervention: Amino acids (); Granisetron (); Lanreotide (); Ondansetron (); RYZ101 (); Sunitinib (); Zofran (Ondansetron); everolimus (RAD001); octreotide LAR ()
    Status: Open

    Clinical Trial 21665
    Randomized Phase II Trial of Postoperative Adjuvant Capecitabine And Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors
    Condition: Gastrointestinal Tumor
    Intervention: Standard of Care (); Temodal (Temozolomide); Temozolomide (); Xeloda (capecitabine); capecitabine ()
    Status: Open

    Clinical Trial 21712
    A Phase 2 Open Label Study to Evaluate the Safety and Effectiveness of 212Pb-DOTAMTATE in PRRT Naïve Subjects with Somatostatin Receptor Expressing Neuroendocrine Tumors
    Condition: Gastrointestinal Tumor
    Intervention: Pb-DOTAMTATE ()
    Status: Open

    If you believe you are eligible for one of these trials or studies, please call
    813-745-6100 or toll-free 1-800-679-0775.

  • Publications

    • Borghesani M, Reni A, Lauricella E, Rossi A, Moscarda V, Trevisani E, Torresan I, Al-Toubah T, Filoni E, Luchini C, De Robertis R, Landoni L, Scarpa A, Porta C, Milella M, Strosberg J, Cives M, Cingarlini S. Efficacy and Toxicity Analysis of mFOLFIRINOX in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms. J Natl Compr Canc Ne. 2024 May.1-8. Pubmedid: 38744314.
    • Strosberg JR, Al-Toubah T, El-Haddad G, Lagunes DR, Bodei L. Sequencing of Somatostatin-Receptor-Based Therapies in Neuroendocrine Tumor Patients. J Nucl Med. 2024 Mar.65(3):340-348. Pubmedid: 38238038.
    • Strosberg J, Hofman M, Al-Toubah T, Hope T. Rethinking Dosimetry: The Perils of Extrapolated External-Beam Radiotherapy Constraints to Radionuclide Therapy. J Nucl Med. 2024 Mar.65(3):362-364. Pubmedid: 38212065.
    • Strosberg JR, Al-Toubah T. Surgical management of metastatic neuroendocrine tumors: beyond the realm of evidence-based medicine. Hepatobiliary Surg Nutr. 2024 Jun.13(3):551-553. Pubmedid: 38911215. Pmcid: PMC11190503.
    • Strosberg J, Cives M. Is NETTER-2 a practice-changing trial?. Nat Rev Clin Oncol. 2024 Jul. Pubmedid: 38982247.
    • Kim DW, Kim YC, Kovari BP, Martinez M, Miao R, Yu J, Mehta R, Strosberg J, Imanirad I, Kim RD. Biomarker Analysis from a Phase I/Ib Study of Regorafenib and Nivolumab in Mismatch Repair-Proficient Advanced Refractory Colorectal Cancer. Cancers (Basel). 2024 Jan.16(3). Pubmedid: 38339307. Pmcid: PMC10854756.
    • Tung-Hahn E, El-Haddad G, Strosberg J. Cutaneous Neuroendocrine Metastases of Visceral Origin Responsive to Surgical Resection and Targeted Radionuclide Therapy. Case Rep Dermatol Med. 2024 Feb.2024:8873822. Pubmedid: 38352716. Pmcid: PMC10864049.
    • Al-Toubah T, Schell MJ, Morse B, Haider M, Valone T, Strosberg J. Phase II study of pembrolizumab and lenvatinib in advanced well-differentiated neuroendocrine tumors. ESMO Open. 2024 Apr.9(4):102386. Pubmedid: 38507897. Pmcid: PMC10966166.
    • Singh S, Hope TA, Bergsland EB, Bodei L, Bushnell DL, Chan JA, Chasen BR, Chauhan A, Das S, Dasari A, Del Rivero J, El-Haddad G, Goodman KA, Halperin DM, Lewis MA, Lindwasser OW, Myrehaug S, Raj NP, Reidy-Lagunes DL, Soares HP, Strosberg JR, Kohn EC, Kunz PL. Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meeting. J Natl Cancer Inst. 2023 Sep.115(9):1001-1010. Pubmedid: 37255328. Pmcid: PMC10483264.
    • Al-Toubah T, Pelle E, Hallanger-Johnson J, Haider M, Strosberg J. ACTH-secreting pancreatic neuroendocrine neoplasms: A case-series. J Neuroendocrinol. 2023 Oct.35(10):e13336. Pubmedid: 37688510.
    • Strosberg J, Al-Toubah T, Cives M. In Defense of Neuroendocrine Tumor Trials. JAMA Oncol. 2023 Oct.9(10):1463-1464. Pubmedid: 37615962.
    • Al-Toubah T, Strosberg J, Hallanger-Johnson J, El-Haddad G. Targeted radionuclide therapy in endocrine-related cancers: advances in the last decade. Front Endocrinol (Lausanne). 2023 Nov.14:1187870. Pubmedid: 38053729. Pmcid: PMC10694449.
    • Del Rivero J, Perez K, Kennedy EB, Mittra ES, Vijayvergia N, Arshad J, Basu S, Chauhan A, Dasari AN, Bellizzi AM, Gangi A, Grady E, Howe JR, Ivanidze J, Lewis M, Mailman J, Raj N, Soares HP, Soulen MC, White SB, Chan JA, Kunz PL, Singh S, Halfdanarson TR, Strosberg JR, Bergsland EK. Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline. J Clin Oncol. 2023 Nov.41(32):5049-5067. Pubmedid: 37774329.
    • Abuzakhm SM, Sukrithan V, Fruth B, Qin R, Strosberg J, Hobday TJ, Semrad T, Reidy-Lagunes D, Kindler HL, Kim GP, Knox JJ, Kaubisch A, Villalona-Calero M, Chen H, Erlichman C, Shah MH. A phase II study of bevacizumab and temsirolimus in advanced extra-pancreatic neuroendocrine tumors. Endocr Relat Cancer. 2023 Nov.30(11). Pubmedid: 37702588. Pmcid: PMC10585708.
    • Kunz PL, Graham NT, Catalano PJ, Nimeiri HS, Fisher GA, Longacre TA, Suarez CJ, Martin BA, Yao JC, Kulke MH, Hendifar AE, Shanks JC, Shah MH, Zalupski MM, Schmulbach EL, Reidy-Lagunes DL, Strosberg JR, O'Dwyer PJ, Benson AB. Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211). J Clin Oncol. 2023 Mar.41(7):1359-1369. Pubmedid: 36260828. Pmcid: PMC9995105.
    • Das S, Phillips S, Lee CL, Agarwal R, Bergsland E, Strosberg J, Chan JA, LaFerriere H, Ramirez RA, Berlin J, Dasari A. Efficacy and toxicity of anti-vascular endothelial growth receptor tyrosine kinase inhibitors in patients with neuroendocrine tumours - A systematic review and meta-analysis. Eur J Cancer. 2023 Mar.182:43-52. Pubmedid: 36738541.
    • Askari E, Moghadam SZ, Wild D, Delpassand E, Baldari S, Nilica B, Hartrampf PE, Kong G, Grana CM, Walter MA, Capoccetti F, Kasi PM, Strosberg J. Peptide Receptor Radionuclide Therapy in Merkel Cell Carcinoma: A Comprehensive Review. J Nucl Med Technol. 2023 Mar.51(1):22-25. Pubmedid: 36195446.
    • Urrego Díaz JA, González M, Romero-Rojas AE, Strosberg J, Jiménez-Vásquez P. Neuroendocrine Tumor Metastases to the Breast: A Case Report and Review of the Literature. Cureus. 2023 Jun.15(6):e40703. Pubmedid: 37485220. Pmcid: PMC10359153.
    • Oliver DE, Laborde JM, Singh DP, Milano MT, Videtic GM, Williams GR, Lariviere MJ, Chan JW, Peters GW, Decker RH, Samson P, Robinson CG, Breen WG, Owen D, Tian S, Higgins KA, Almeldin D, Jabbour SK, Wang F, Grass GD, Perez BA, Dilling TJ, Strosberg J, Rosenberg SA. Early-Stage Primary Lung Neuroendocrine Tumors Treated With Stereotactic Body Radiation Therapy: A Multi-Institution Experience. Int J Radiat Oncol Biol Phys. 2023 Jul.116(4):849-857. Pubmedid: 36708788.
    • Xiao Z, Xu H, Strosberg JR, Lu R, Zhu X, Deng S, Ding L, Ni Q, Warshaw AL, Yu X, Luo G. EGFR is a potential therapeutic target for highly glycosylated and aggressive pancreatic neuroendocrine neoplasms. Int J Cancer. 2023 Jul.153(1):164-172. Pubmedid: 36891979.
    • Strosberg JR, Herrmann K, Bodei L. The Future of Targeted α-Therapy Is Bright, but Rigorous Studies Are Necessary to Advance the Field. J Nucl Med. 2023 Feb.64(2):219-220. Pubmedid: 36265909. Pmcid: PMC9902860.
    • Strosberg JR, Al-Toubah T. Are hemicolectomies justified for appendiceal neuroendocrine tumours smaller than 2 cm?. Lancet Oncol. 2023 Feb.24(2):121-122. Pubmedid: 36640791.
    • Al-Toubah T, Montilla-Soler J, El-Haddad G, Haider M, Strosberg J. Somatostatin Receptor Expression in Lung Neuroendocrine Tumors: An Analysis of DOTATATE PET Scans. J Nucl Med. 2023 Dec.64(12):1895-1898. Pubmedid: 37797976.
    • Morse B, Strosberg J. Multiple Tumors in a Young Patient. Gastroenterology. 2022 Sep.163(3):e13-e15. Pubmedid: 35248537.
    • Gosain R, Gupta M, Roy AM, Strosberg J, Glaser KM, Iyer R. Health-Related Quality of Life (HRQoL) in Neuroendocrine Tumors: A Systematic Review. Cancers (Basel). 2022 Mar.14(6). Pubmedid: 35326587. Pmcid: PMC8946839.
    • Xu A, Suz P, Reljic T, Are AC, Kumar A, Powers B, Strosberg J, Denbo JW, Fleming JB, Anaya DA. Perioperative Carcinoid Crisis: A Systematic Review and Meta-Analysis. Cancers (Basel). 2022 Jun.14(12). Pubmedid: 35740631. Pmcid: PMC9221110.
    • Mandriani B, Pellè E, Mannavola F, Palazzo A, Marsano RM, Ingravallo G, Cazzato G, Ramello MC, Porta C, Strosberg J, Abate-Daga D, Cives M. Development of anti-somatostatin receptors CAR T cells for treatment of neuroendocrine tumors. J Immunother Cancer. 2022 Jun.10(6). Pubmedid: 35764366. Pmcid: PMC9240886.
    • Kim RD, Kovari BP, Martinez M, Xie H, Sahin IH, Mehta R, Strosberg J, Imanirad I, Ghayouri M, Kim YC, Kim DW. A phase I/Ib study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer. Eur J Cancer. 2022 Jul.169:93-102. Pubmedid: 35526308.
    • Al-Toubah T, Morse B, Strosberg J. Efficacy of Capecitabine and Temozolomide in Small Bowel (Midgut) Neuroendocrine Tumors. Curr Oncol. 2022 Jan.29(2):510-515. Pubmedid: 35200546. Pmcid: PMC8870244.
    • Al-Toubah T, Halfdanarson T, Gile J, Morse B, Sommerer K, Strosberg J. Efficacy of ipilimumab and nivolumab in patients with high-grade neuroendocrine neoplasms. ESMO Open. 2022 Feb.7(1):100364. Pubmedid: 34973511. Pmcid: PMC8728436.
    • Pelle E, Al-Toubah T, Morse B, Strosberg J. Belzutifan in a Patient With VHL-Associated Metastatic Pancreatic Neuroendocrine Tumor. J Natl Compr Canc Ne. 2022 Dec.20(12):1285-1287. Pubmedid: 36509068.
    • DeCarli K, Strosberg J, Almhanna K. Immune Checkpoint Inhibitors for Gastrointestinal Malignancies: An Update. Cancers (Basel). 2022 Aug.14(17). Pubmedid: 36077740. Pmcid: PMC9454768.
    • Strosberg JR, El-Haddad G, Al-Toubah T, Reidy D, Ziv E, Mahvash A, Dasari A, Philip P, Soulen MC. Radioembolization Versus Bland or Chemoembolization for Liver-Dominant Neuroendocrine Tumors: Is it an Either/Or Question?. J Nucl Med. 2021 Sep. Pubmedid: 34556527. Pmcid: PMC8612204.
    • Das S, Al-Toubah T, Strosberg J. Chemotherapy in Neuroendocrine Tumors. Cancers (Basel). 2021 Sep.13(19). Pubmedid: 34638356. Pmcid: PMC8507720.
    • Strosberg JR, Al-Toubah T, El-Haddad G. Reply: Bowel Obstruction as a Complication of Peptide Receptor Radionuclide Therapy. J Nucl Med. 2021 Sep.62(9):1321. Pubmedid: 34244354.
    • Patel SP, Mayerson E, Chae YK, Strosberg J, Wang J, Konda B, Hayward J, McLeod CM, Chen HX, Sharon E, Othus M, Ryan CW, Plets M, Blanke CD, Kurzrock R. A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: High-grade neuroendocrine neoplasm cohort. Cancer. 2021 Sep.127(17):3194-3201. Pubmedid: 33882143. Pmcid: PMC8606104.
    • Eng C, Chen EY, Rogers J, Lewis M, Strosberg J, Thota R, Krishnamurthi S, Oberstein P, Govindarajan R, Buchschacher G, Patel S, Sohal D, Al-Toubah T, Philip P, Dasari A, Kennecke H, Stein S. Moving Beyond the Momentum: Innovative Approaches to Clinical Trial Implementation. JCO Oncol Pract. 2021 Oct.17(10):607-614. Pubmedid: 33534616. Pmcid: PMC8791825.
    • Tafreshi NK, Pandya DN, Tichacek CJ, Budzevich MM, Wang Z, Reff JN, Engelman RW, Boulware DC, Chiappori AA, Strosberg JR, Ji H, Wadas TJ, El-Haddad G, Morse DL. Preclinical evaluation of [225Ac]Ac-DOTA-TATE for treatment of lung neuroendocrine neoplasms. Eur J Nucl Med Mol Imaging. 2021 Oct.48(11):3408-3421. Pubmedid: 33772332.
    • Zhu M, Costello BA, Yin J, Pettinger AM, Strosberg JR, Erlichman C, Hobday TJ. Phase II Trial of Bevacizumab Monotherapy in Pancreatic Neuroendocrine Tumors. Pancreas. 2021 Nov.50(10):1435-1439. Pubmedid: 35041344.
    • Mandriani B, Pelle' E, Pezzicoli G, Strosberg J, Abate-Daga D, Guarini A, Cives M, Porta C. Adoptive T-cell immunotherapy in digestive tract malignancies: Current challenges and future perspectives. Cancer Treat Rev. 2021 Nov.100:102288. Pubmedid: 34525422.
    • Kim DW, Tan E, Zhou JM, Schell MJ, Martinez M, Yu J, Carballido E, Mehta R, Strosberg J, Imanirad I, Kim RD. A phase 1/2 trial of ibrutinib in combination with pembrolizumab in patients with mismatch repair proficient metastatic colorectal cancer. Brit J Cancer. 2021 May.124(11):1803-1808. Pubmedid: 33828254. Pmcid: PMC8144213.
    • Ambrosini V, Kunikowska J, Baudin E, Bodei L, Bouvier C, Capdevila J, Cremonesi M, de Herder WW, Dromain C, Falconi M, Fani M, Fanti S, Hicks RJ, Kabasakal L, Kaltsas G, Lewington V, Minozzi S, Cinquini M, Öberg K, Oyen WJG, O'Toole D, Pavel M, Ruszniewski P, Scarpa A, Strosberg J, Sundin A, Taïeb D, Virgolini I, Wild D, Herrmann K, Yao J. Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. Eur J Cancer. 2021 Mar.146:56-73. Pubmedid: 33588146. Pmcid: PMC8903070.
    • Haider M, Das S, Al-Toubah T, Pelle E, El-Haddad G, Strosberg J. Somatostatin receptor radionuclide therapy in neuroendocrine tumors. Endocr Relat Cancer. 2021 Mar.28(3):R81-R93. Pubmedid: 33608483. Pmcid: PMC8118168.
    • Strosberg JR, Srirajaskanthan R, El-Haddad G, Wolin EM, Chasen BR, Kulke MH, Bushnell DL, Caplin ME, Baum RP, Hendifar AE, Öberg K, Ruszniewski P, Santoro P, Broberg P, Leeuwenkamp OR, Krenning EP. Symptom Diaries of Patients with Midgut Neuroendocrine Tumors Treated with 177Lu-DOTATATE. J Nucl Med. 2021 Mar. Pubmedid: 33771903. Pmcid: PMC8612179.
    • Jha A, Taieb D, Carrasquillo JA, Pryma DA, Patel M, Millo C, de Herder WW, Del Rivero J, Crona J, Shulkin BL, Virgolini I, Chen AP, Mittal BR, Basu S, Dillon JS, Hope TA, Mari Aparici C, Iagaru A, Hicks RJ, Avram AM, Strosberg JR, Civelek AC, Lin FI, Pandit-Taskar N, Pacak K. High-Specific-Activity-131I-MIBG versus 177Lu-DOTATATE Targeted Radionuclide Therapy for Metastatic Pheochromocytoma and Paraganglioma. Clin Cancer Res. 2021 Jun.27(11):2989-2995. Pubmedid: 33685867. Pmcid: PMC8172462.
    • Strosberg J, Leeuwenkamp O, Siddiqui MK. Corrigendum to "Peptide receptor radiotherapy re-treatment in patients with progressive neuroendocrine tumors: A systematic review and meta-analysis" [Cancer Treatm. Rev. 93 (2021) 102141]. Cancer Treat Rev. 2021 Jun.97:102203. Pubmedid: 33857824.
    • Shah MH, Goldner WS, Benson AB, Bergsland E, Blaszkowsky LS, Brock P, Chan J, Das S, Dickson PV, Fanta P, Giordano T, Halfdanarson TR, Halperin D, He J, Heaney A, Heslin MJ, Kandeel F, Kardan A, Khan SA, Kuvshinoff BW, Lieu C, Miller K, Pillarisetty VG, Reidy D, Salgado SA, Shaheen S, Soares HP, Soulen MC, Strosberg JR, Sussman CR, Trikalinos NA, Uboha NA, Vijayvergia N, Wong T, Lynn B, Hochstetler C. Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Ne. 2021 Jul.19(7):839-868. Pubmedid: 34340212.
    • Yao JC, Strosberg J, Fazio N, Pavel ME, Bergsland E, Ruszniewski P, Halperin DM, Li D, Tafuto S, Raj N, Campana D, Hijioka S, Raderer M, Guimbaud R, Gajate P, Pusceddu S, Reising A, Degtyarev E, Shilkrut M, Eddy S, Singh S. Spartalizumab in metastatic, well/poorly-differentiated neuroendocrine neoplasms. Endocr Relat Cancer. 2021 Jan. Pubmedid: 33480358.
    • Strosberg JR, Al-Toubah T, Pellè E, Smith J, Haider M, Hutchinson T, Fleming JB, El-Haddad G. Risk of Bowel Obstruction in Patients with Mesenteric or Peritoneal Disease Receiving Peptide Receptor Radionuclide Therapy. J Nucl Med. 2021 Jan.62(1):69-72. Pubmedid: 32444368.
    • Pelle E, Al-Toubah T, Morse B, El-Haddad G, Strosberg J. Desmoplastic mesenteric lesions do not respond radiographically to peptide receptor radionuclide therapy. J Neuroendocrinol. 2021 Feb.33(2):e12936. Pubmedid: 33474756.
    • Chan DL, Yao JC, Carnaghi C, Buzzoni R, Herbst F, Ridolfi A, Strosberg J, Kulke MH, Pavel M, Singh S. Markers of Systemic Inflammation in Neuroendocrine Tumors: A Pooled Analysis of the RADIANT-3 and RADIANT-4 Studies. Pancreas. 2021 Feb.50(2):130-137. Pubmedid: 33560090.
    • Al-Toubah T, Morse B, Pelle E, Strosberg J. Efficacy of FOLFOX in Patients with Aggressive Pancreatic Neuroendocrine Tumors After Prior Capecitabine/Temozolomide. Oncologist. 2021 Feb.26(2):115-119. Pubmedid: 33225478. Pmcid: PMC7873336.
    • Al-Toubah T, Grozinsky-Glasberg S, Strosberg J. An Update on the Management of Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia (DIPNECH). CURR TREAT OPTION ON. 2021 Feb.22(4):28. Pubmedid: 33641079.
    • Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, Mittra E, Wolin EM, Yao JC, Pavel ME, Grande E, Van Cutsem E, Seregni E, Duarte H, Gericke G, Bartalotta A, Mariani MF, Demange A, Mutevelic S, Krenning EP. 177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021 Dec.22(12):1752-1763. Pubmedid: 34793718.
    • Al-Toubah T, Pelle E, Valone T, Haider M, Strosberg JR. Efficacy and Toxicity Analysis of Capecitabine and Temozolomide in Neuroendocrine Neoplasms. J Natl Compr Canc Ne. 2021 Aug.20(1):29-36. Pubmedid: 34433130.
    • Fazio N, Carnaghi C, Buzzoni R, Valle JW, Herbst F, Ridolfi A, Strosberg J, Kulke MH, Pavel ME, Yao JC. Relationship between metabolic toxicity and efficacy of everolimus in patients with neuroendocrine tumors: A pooled analysis from the randomized, phase 3 RADIANT-3 and RADIANT-4 trials. Cancer. 2021 Aug.127(15):2674-2682. Pubmedid: 33857327.
    • Al-Toubah T, Sikaria D, Jesurajan J, Bottiglieri S, Smith J, Pellé E, Hutchinson T, Strosberg J, El-Haddad G. Comparison of Nausea and Vomiting Associated With Amino Acid Formulations Coinfused With Peptide Receptor Radionuclide Therapy: Commercial Parenteral Nutrition Formulas Versus Compounded Arginine/Lysine. Pancreas. 2021 Apr.50(4):513-515. Pubmedid: 33939662.
    • Merola E, Alonso Gordoa T, Zhang P, Al-Toubah T, Pelle E, Kolasińska-Ćwikła A, Zandee WT, Laskaratos FM, de Mestier L, Lamarca A, Hernando J, Cwikla JB, Strosberg J, de Herder WW, Caplin M, Cives M, van Leeuwaarde RS. Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Any Benefit When Ki-67 Is ≥10%?. Oncologist. 2021 Apr.26(4):294-301. Pubmedid: 33301235. Pmcid: PMC8018333.
    • Al-Toubah T, Strosberg J. Progress in TNM staging of pancreatic neuroendocrine tumors. Hepatobiliary Surg Nutr. 2021 Apr.10(2):238-240. Pubmedid: 33898566. Pmcid: PMC8050571.
    • Chan H, Zhang L, Choti MA, Kulke M, Yao JC, Nakakura EK, Bloomston M, Benson AB, Shah MH, Strosberg JR, Bergsland EK, Van Loon K. Recurrence Patterns After Surgical Resection of Gastroenteropancreatic Neuroendocrine Tumors: Analysis From the National Comprehensive Cancer Network Oncology Outcomes Database. Pancreas. 2021 Apr.50(4):506-512. Pubmedid: 33939661. Pmcid: PMC8097723.
    • Bodei L, Schöder H, Baum RP, Herrmann K, Strosberg J, Caplin M, Öberg K, Modlin IM. Molecular profiling of neuroendocrine tumours to predict response and toxicity to peptide receptor radionuclide therapy. Lancet Oncol. 2020 Sep.21(9):e431-e443. Pubmedid: 32888472. Pmcid: PMC8385643.
    • Strosberg J, Kunz PL, Hendifar A, Yao J, Bushnell D, Kulke MH, Baum RP, Caplin M, Ruszniewski P, Delpassand E, Hobday T, Verslype C, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Paganelli G, Severi S, Morse M, Metz DC, Ansquer C, Courbon F, Al-Nahhas A, Baudin E, Giammarile F, Taïeb D, Mittra E, Wolin E, O'Dorisio TM, Lebtahi R, Deroose CM, Grana CM, Bodei L, Öberg K, Polack BD, He B, Mariani MF, Gericke G, Santoro P, Erion JL, Ravasi L, Krenning E. Impact of liver tumour burden, alkaline phosphatase elevation, and target lesion size on treatment outcomes with 177Lu-Dotatate: an analysis of the NETTER-1 study. Eur J Nucl Med Mol Imaging. 2020 Sep.47(10):2372-2382. Pubmedid: 32123969. Pmcid: PMC7396396.
    • Singh S, Bergsland EK, Card CM, Hope TA, Kunz PL, Laidley DT, Lawrence B, Leyden S, Metz DC, Michael M, Modahl LE, Myrehaug S, Padda SK, Pommier RF, Ramirez RA, Soulen M, Strosberg J, Sung A, Thawer A, Wei B, Xu B, Segelov E. Commonwealth Neuroendocrine Tumour Research Collaboration and the North American Neuroendocrine Tumor Society Guidelines for the Diagnosis and Management of Patients With Lung Neuroendocrine Tumors: An International Collaborative Endorsement and Update of. J Thorac Oncol. 2020 Oct.15(10):1577-1598. Pubmedid: 32663527.
    • Al-Toubah T, Pelle E, Strosberg J. What is the role of checkpoint inhibitors in neuroendocrine neoplasms?. Oncotarget. 2020 Oct.11(42):3751-3752. Pubmedid: 33144916. Pmcid: PMC7584236.
    • Al-Toubah T, Cives M, Strosberg J. Novel immunotherapy strategies for treatment of neuroendocrine neoplasms. Transl Gastroenterol Hepatol. 2020 Oct.5:54. Pubmedid: 33073049. Pmcid: PMC7530319.
    • Cives M, Pelle' E, Strosberg J. Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors. J Clin Med. 2020 Nov.9(11). Pubmedid: 33202931. Pmcid: PMC7696369.
    • Strosberg JR, Mizuno N, Doi T, Grande E, Delord JP, Shapira-Frommer R, Bergsland EK, Shah MH, Fakih M, Takahashi S, Piha-Paul SA, O'Neil BH, Thomas S, Lolkema M, Chen M, Ibrahim N, Norwood KG, Hadoux J. Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study. Clin Cancer Res. 2020 May.26(9):2124-2130. Pubmedid: 31980466. Pmcid: PMC7811789.
    • Benson AB, Strosberg J, Joish VN, Dharba S, Sapre D, Lapuerta P. Clinical Benefits of Telotristat Ethyl in Patients With Neuroendocrine Tumors and Low Bowel Movement Frequency: An Observational Patient-Reported Outcomes Study. Pancreas. 2020 Mar.49(3):408-412. Pubmedid: 32132510.
    • Al-Toubah T, Cives M, Valone T, Blue K, Strosberg JR. Sensitivity and Specificity of the NETest: A Validation Study. Neuroendocrinology. 2020 Jul.111(6):580-585. Pubmedid: 32615553.
    • Al-Toubah T, Strosberg J, Halfdanarson T, Oleinikov K, Gross DJ, Haider M, Sonbol MB, Almquist D, Grozinsky-Glasberg S. Somatostatin Analogs Improve Respiratory Symptoms in Patients With Diffuse Idiopathic Neuroendocrine Cell Hyperplasia. Chest. 2020 Jul.158(1):401-405. Pubmedid: 32059961.
    • Al-Toubah T, Morse B, Strosberg J. Capecitabine and Temozolomide in Advanced Lung Neuroendocrine Neoplasms. Oncologist. 2020 Jan.25(1):e48-e52. Pubmedid: 31455747. Pmcid: PMC6964126.
    • Öberg K, Califano A, Strosberg JR, Ma S, Pape U, Bodei L, Kaltsas G, Toumpanakis C, Goldenring JR, Frilling A, Paulson S. A meta-analysis of the accuracy of a neuroendocrine tumor mRNA genomic biomarker (NETest) in blood. Ann Oncol. 2020 Feb.31(2):202-212. Pubmedid: 31959337.
    • Sunjic I, Shin D, Sunjic KM, Popat JV, Tran T, Chae SH, Caldeira CC, Strosberg JR, Sayad D. Incidence of Atrioventricular Block After Valve Replacement in Carcinoid Heart Disease. Cardiol Res. 2020 Feb.11(1):56-60. Pubmedid: 32095197. Pmcid: PMC7011921.
    • Haider M, Al-Toubah T, El-Haddad G, Strosberg J. Molecular imaging and radionuclide therapy of neuroendocrine tumors. Curr Opin Endocrinol Diabetes Obes. 2020 Feb.27(1):16-21. Pubmedid: 31789833.
    • Hope TA, Bodei L, Chan JA, El-Haddad G, Fidelman N, Kunz PL, Mailman J, Menda Y, Metz DC, Mittra ES, Pryma DA, Reidy-Lagunes DL, Singh S, Strosberg JR. NANETS/SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy. J Nucl Med. 2020 Feb.61(2):222-227. Pubmedid: 32015164. Pmcid: PMC9364765.
    • Strosberg J, Leeuwenkamp O, Siddiqui MK. Peptide receptor radiotherapy re-treatment in patients with progressive neuroendocrine tumors: A systematic review and meta-analysis. Cancer Treat Rev. 2020 Dec.93:102141. Pubmedid: 33418096.
    • Powers BD, Rothermel LD, Fleming JB, Strosberg JR, Anaya DA. A Survival Analysis of Patients with Localized, Asymptomatic Pancreatic Neuroendocrine Tumors: No Surgical Survival Benefit when Examining Appropriately Selected Outcomes. J Gastrointest Surg. 2020 Dec.24(12):2773-2779. Pubmedid: 31754990.
    • Bodei L, Bergsland EK, de Herder WK, Ferone D, Hicks RJ, Hope TA, Kunikowska JA, Pavel M, Reidy-Lagunes DL, Siveke J, Strosberg JR, Dittmer U, Herrmann K. Peptide Receptor Radionuclide Therapy During the COVID-19 Pandemic: Are There Any Concerns?. J Nucl Med. 2020 Aug.61(8):1094-1095. Pubmedid: 32576637. Pmcid: PMC7413236.
    • Halfdanarson TR, Strosberg JR, Tang L, Bellizzi AM, Bergsland EK, OʼDorisio TM, Halperin DM, Fishbein L, Eads J, Hope TA, Singh S, Salem R, Metz DC, Naraev BG, Reidy-Lagunes DL, Howe JR, Pommier RF, Menda Y, Chan JA. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Pancreatic Neuroendocrine Tumors. Pancreas. 2020 Aug.49(7):863-881. Pubmedid: 32675783.
    • Vijayvergia N, Dasari A, Deng M, Litwin S, Al-Toubah T, Alpaugh RK, Dotan E, Hall MJ, Ross NM, Runyen MM, Denlinger CS, Halperin DM, Cohen SJ, Engstrom PF, Strosberg JR. Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trials. Brit J Cancer. 2020 Apr.122(9):1309-1314. Pubmedid: 32152503. Pmcid: PMC7188798.
    • Kis B, Mills M, Smith J, Choi J, Sagatys E, Komrokji R, Strosberg J, Kim RD. Partial Splenic Artery Embolization in 35 Cancer Patients: Results of a Single Institution Retrospective Study. J Vasc Interv Radiol. 2020 Apr.31(4):584-591. Pubmedid: 31471193.
    • Saller J, Seydafkan S, Shahid M, Gadara M, Cives M, Eschrich SA, Boulware D, Strosberg JR, Aejaz N, Coppola D. EPB41L5 is Associated With the Metastatic Potential of Low-grade Pancreatic Neuroendocrine Tumors. Cancer Genomics Proteomics. 2019 Sep.16(5):309-318. Pubmedid: 31467225. Pmcid: PMC6727072.
    • Das S, Al-Toubah T, El-Haddad G, Strosberg J. 177Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors. Expert Rev Gastroenterol Hepatol. 2019 Oct.13(11):1023-1031. Pubmedid: 31652074. Pmcid: PMC7227421.
    • Shahid M, George TB, Saller J, Haija M, Sayegh Z, Boulware D, Strosberg J, Chakrabarti R, Coppola D. FGD4 (Frabin) Overexpression in Pancreatic Neuroendocrine Neoplasms. Pancreas. 2019 Nov.48(10):1307-1311. Pubmedid: 31688594. Pmcid: PMC7771383.
    • Strosberg J, Joish VN, Giacalone S, Perez-Olle R, Fish-Steagall A, Kapoor K, Dharba S, Lapuerta P, Benson AB. TELEPRO: Patient-Reported Carcinoid Syndrome Symptom Improvement Following Initiation of Telotristat Ethyl in the Real World. Oncologist. 2019 Nov.24(11):1446-1452. Pubmedid: 31189618. Pmcid: PMC6853091.
    • Xie H, Liu J, Yadav S, Keutgen X, Hobday T, Strosberg JR, Halfdanarson T. The Role of Perioperative Systemic Therapy in Localized Pancreatic Neuroendocrine Neoplasms. Neuroendocrinology. 2019 May.110(3-4):234-245. Pubmedid: 31121586.
    • Halperin DM, Lee JJ, Ng CS, Strosberg JR, Estrella JS, Dagohoy CG, Dasari A, Yao JC. A Phase II Trial of Ziv-Aflibercept in Patients With Advanced Pancreatic Neuroendocrine Tumors. Pancreas. 2019 Mar.48(3):381-386. Pubmedid: 30768575.
    • Mohamed A, Strosberg JR. Medical Management of Gastroenteropancreatic Neuroendocrine Tumors: Current Strategies and Future Advances. J Nucl Med. 2019 Jun.60(6):721-727. Pubmedid: 30737297.
    • Dhaliwal AJS, Strosberg JR, Centeno BA, Vignesh S. Diagnostic performance of endoscopic ultrasound-guided fine-needle aspiration for cystic and non-cystic pancreatic neuroendocrine tumors. Endosc Int Open. 2019 Jul.7(7):E854-E859. Pubmedid: 31286055. Pmcid: PMC6611730.
    • Al-Toubah T, Schell M, Cives M, Zhou JM, Soares H, Strosberg JR. A Phase II Study of Ibrutinib in Advanced Neuroendocrine Neoplasms. Neuroendocrinology. 2019 Jul.110(5):377-383. Pubmedid: 31357193. Pmcid: PMC7771542.
    • Hope TA, Abbott A, Colucci K, Bushnell DL, Gardner L, Graham WS, Lindsay S, Metz DC, Pryma DA, Stabin MG, Strosberg JR. NANETS/SNMMI Procedure Standard for Somatostatin Receptor-Based Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE. J Nucl Med. 2019 Jul.60(7):937-943. Pubmedid: 31263080.
    • Hendifar AE, Dhall D, Strosberg JR. The Evolving Treatment Algorithm for Advanced Neuroendocrine Neoplasms: Diversity and Commonalities Across Tumor Types. Oncologist. 2019 Jan.24(1):54-61. Pubmedid: 30104288. Pmcid: PMC6324634.
    • Cives M, Strosberg J, Al Diffalha S, Coppola D. Analysis of the immune landscape of small bowel neuroendocrine tumors. Endocr Relat Cancer. 2019 Jan.26(1):119-130. Pubmedid: 30400003. Pmcid: PMC7787268.
    • Chan DL, Moody L, Segelov E, Metz D, Strosberg J, Pavlakis N, Singh S. Follow-Up for Resected Gastroenteropancreatic Neuroendocrine Tumours: A Practice Survey of the Commonwealth Neuroendocrine Tumour Collaboration (CommNETS) and the North American Neuroendocrine Tumor Society (NANETS). Neuroendocrinology. 2019 Jan.107(1):32-41. Pubmedid: 29539613.
    • Chauhan N, Mulcahy MF, Salem R, Benson Iii AB, Boucher E, Bukovcan J, Cosgrove D, Laframboise C, Lewandowski RJ, Master F, El-Rayes B, Strosberg JR, Sze DY, Sharma RA. TheraSphere Yttrium-90 Glass Microspheres Combined With Chemotherapy Versus Chemotherapy Alone in Second-Line Treatment of Patients With Metastatic Colorectal Carcinoma of the Liver: Protocol for the EPOCH Phase 3 Randomized Clinical Trial. JMIR Res Protoc. 2019 Jan.8(1):e11545. Pubmedid: 30664496. Pmcid: PMC6354199.
    • Barnebee D, Morse B, Strosberg JR, Pejic M, Jeong D. Cardiac Magnetic Resonance for Diagnosis of Neuroendocrine Tumor Metastases to the Right and Left Ventricles with Carcinoid Heart Disease. Case Rep Cardiol. 2019 Dec.2019:8746413. Pubmedid: 31885933. Pmcid: PMC6915124.
    • Cives M, Partelli S, Palmirotta R, Lovero D, Mandriani B, Quaresmini D, Pelle' E, Andreasi V, Castelli P, Strosberg J, Zamboni G, Falconi M, Silvestris F. DAXX mutations as potential genomic markers of malignant evolution in small nonfunctioning pancreatic neuroendocrine tumors. Sci Rep. 2019 Dec.9(1):18614. Pubmedid: 31819132. Pmcid: PMC6901561.
    • Al-Toubah T, Partelli S, Cives M, Andreasi V, Silvestris F, Falconi M, Anaya Saenz D, Strosberg J. Local treatment for focal progression in metastatic neuroendocrine tumors. Endocr Relat Cancer. 2019 Apr.26(4):405-409. Pubmedid: 30668527.
    • Strosberg JR, Al-Toubah T, Cives M. Evaluating Risks and Benefits of Evolving Systemic Treatments of Neuroendocrine Tumors. JAMA Oncol. 2019 Apr.5(4):489-490. Pubmedid: 30763444.
    • Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, Baum RP, Kunz P, Hobday T, Hendifar A, Oberg K, Sierra ML, Thevenet T, Margalet I, Ruszniewski P, Krenning E. Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 Trial. J Clin Oncol. 2018 Sep.36(25):2578-2584. Pubmedid: 29878866. Pmcid: PMC6366953.
    • Al-Toubah T, Strosberg J. Peptide Receptor Radiotherapy Comes of Age. Endocrin Metab Clin. 2018 Sep.47(3):615-625. Pubmedid: 30098719.
    • Strosberg J. Lutetium-Dotatate delays decline in quality of life in patients with midgut neuroendocrine tumors. Oncotarget. 2018 Sep.9(69):33059. Pubmedid: 30237849. Pmcid: PMC6145708.
    • Singh S, Moody L, Chan DL, Metz DC, Strosberg J, Asmis T, Bailey DL, Bergsland E, Brendtro K, Carroll R, Cleary S, Kim M, Kong G, Law C, Lawrence B, McEwan A, McGregor C, Michael M, Pasieka J, Pavlakis N, Pommier R, Soulen M, Wyld D, Segelov E. Follow-up Recommendations for Completely Resected Gastroenteropancreatic Neuroendocrine Tumors. JAMA Oncol. 2018 Nov.4(11):1597-1604. Pubmedid: 30054622.
    • Cives M, Strosberg JR. Gastroenteropancreatic Neuroendocrine Tumors. CA-Cancer J Clin. 2018 Nov.68(6):471-487. Pubmedid: 30295930.
    • Raj N, Fazio N, Strosberg J. Biology and Systemic Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors. Am Soc Clin Oncol Educ Book. 2018 May.38:292-299. Pubmedid: 30231344.
    • Cives M, Anaya DA, Soares H, Coppola D, Strosberg J. Analysis of Postoperative Recurrence in Stage I-III Midgut Neuroendocrine Tumors. J Natl Cancer Inst. 2018 Mar.110(3):282-289. Pubmedid: 29741649.
    • Chi W, Warner RRP, Chan DL, Singh S, Segelov E, Strosberg J, Wisnivesky J, Kim MK. Long-term Outcomes of Gastroenteropancreatic Neuroendocrine Tumors. Pancreas. 2018 Mar.47(3):321-325. Pubmedid: 29401168.
    • Shah MH, Goldner WS, Halfdanarson TR, Bergsland E, Berlin JD, Halperin D, Chan J, Kulke MH, Benson AB, Blaszkowsky LS, Eads J, Engstrom PF, Fanta P, Giordano T, He J, Heslin MJ, Kalemkerian GP, Kandeel F, Khan SA, Kidwai WZ, Kunz PL, Kuvshinoff BW, Lieu C, Pillarisetty VG, Saltz L, Sosa JA, Strosberg JR, Sussman CA, Trikalinos NA, Uboha NA, Whisenant J, Wong T, Yao JC, Burns JL, Ogba N, Zuccarino-Catania G. NCCN Guidelines Insights: Neuroendocrine and Adrenal Tumors, Version 2.2018. J Natl Compr Canc Ne. 2018 Jun.16(6):693-702. Pubmedid: 29891520.
    • Fazio N, Buzzoni R, Delle Fave G, Tesselaar ME, Wolin E, Van Cutsem E, Tomassetti P, Strosberg J, Voi M, Pacaud LB, Ridolfi A, Herbst F, Tomasek J, Singh S, Pavel M, Kulke MH, Valle JW, Yao JC. Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis. Cancer Sci. 2018 Jan.109(1):174-181. Pubmedid: 29055056. Pmcid: PMC5765303.
    • Grothey A, Strosberg JR, Renfro LA, Hurwitz HI, Marshall J, Safran H, Guarino MJ, Kim GP, Hecht JR, Weil SC, Heyburn J, Wang W, Schweizer C, O'Shannessy DJ, Diaz LA. A Randomized, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Monotherapy Ontuxizumab (MORAb-004) Plus Best Supportive Care in Patients with Chemorefractory Metastatic Colorectal Cancer. Clin Cancer Res. 2018 Jan.24(2):316-325. Pubmedid: 29084918.
    • Denson A, Burke N, Wapinsky G, Bertels B, Juan TH, Lee J, Springett GM, Strosberg JR, Kim RD, Sullivan DM, Mahipal A. Clinical Outcomes of Patients With Gastrointestinal Malignancies Participating in Phase I Clinical Trials. Am J Clin Oncol. 2018 Feb.41(2):133-139. Pubmedid: 26523441. Pmcid: PMC4980275.
    • Morse B, Jeong D, Thomas K, Diallo D, Strosberg JR. Magnetic Resonance Imaging of Neuroendocrine Tumor Hepatic Metastases: Does Hepatobiliary Phase Imaging Improve Lesion Conspicuity and Interobserver Agreement of Lesion Measurements?. Pancreas. 2017 Oct.46(9):1219-1224. Pubmedid: 28902795.
    • Buzzoni R, Carnaghi C, Strosberg J, Fazio N, Singh S, Herbst F, Ridolfi A, Pavel ME, Wolin EM, Valle JW, Oh DY, Yao JC, Pommier R. Impact of prior therapies on everolimus activity: an exploratory analysis of RADIANT-4. Onco Targets Ther. 2017 Oct.10:5013-5030. Pubmedid: 29081664. Pmcid: PMC5652899.
    • Pavel ME, Singh S, Strosberg JR, Bubuteishvili-Pacaud L, Degtyarev E, Neary MP, Carnaghi C, Tomasek J, Wolin E, Raderer M, Lahner H, Valle JW, Pommier R, Van Cutsem E, Tesselaar MET, Fave GD, Buzzoni R, Hunger M, Eriksson J, Cella D, Ricci JF, Fazio N, Kulke MH, Yao JC. Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 t. Lancet Oncol. 2017 Oct.18(10):1411-1422. Pubmedid: 28838862.
    • Yao JC, Guthrie KA, Moran C, Strosberg JR, Kulke MH, Chan JA, LoConte N, McWilliams RR, Wolin EM, Mattar B, McDonough S, Chen H, Blanke CD, Hochster HS. Phase III Prospective Randomized Comparison Trial of Depot Octreotide Plus Interferon Alfa-2b Versus Depot Octreotide Plus Bevacizumab in Patients With Advanced Carcinoid Tumors: SWOG S0518. J Clin Oncol. 2017 May.35(15):1695-1703. Pubmedid: 28384065. Pmcid: PMC5455764.
    • Cives M, Strosberg J. Treatment Strategies for Metastatic Neuroendocrine Tumors of the Gastrointestinal Tract. CURR TREAT OPTION ON. 2017 Mar.18(3):14. Pubmedid: 28286921.
    • Yao JC, Chan JA, Mita AC, Kundu MG, Hermosillo Reséndiz K, Hu K, Ravichandran S, Strosberg JR, Wolin EM. Phase I dose-escalation study of long-acting pasireotide in patients with neuroendocrine tumors. Onco Targets Ther. 2017 Jun.10:3177-3186. Pubmedid: 28721067. Pmcid: PMC5499931.
    • Hamiditabar M, Ali M, Roys J, Wolin EM, OʼDorisio TM, Ranganathan D, Tworowska I, Strosberg JR, Delpassand ES. Peptide Receptor Radionuclide Therapy With 177Lu-Octreotate in Patients With Somatostatin Receptor Expressing Neuroendocrine Tumors: Six Years' Assessment. Clin Nucl Med. 2017 Jun.42(6):436-443. Pubmedid: 28263217. Pmcid: PMC7733354.
    • Strosberg JR, Halfdanarson TR, Bellizzi AM, Chan JA, Dillon JS, Heaney AP, Kunz PL, O'Dorisio TM, Salem R, Segelov E, Howe JR, Pommier RF, Brendtro K, Bashir MA, Singh S, Soulen MC, Tang L, Zacks JS, Yao JC, Bergsland EK. The North American Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Medical Management of Midgut Neuroendocrine Tumors. Pancreas. 2017 Jul.46(6):707-714. Pubmedid: 28609356. Pmcid: PMC5642985.
    • Howe JR, Cardona K, Fraker DL, Kebebew E, Untch BR, Wang YZ, Law CH, Liu EH, Kim MK, Menda Y, Morse BG, Bergsland EK, Strosberg JR, Nakakura EK, Pommier RF. The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society. Pancreas. 2017 Jul.46(6):715-731. Pubmedid: 28609357. Pmcid: PMC5502737.
    • Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, Mittra E, Kunz PL, Kulke MH, Jacene H, Bushnell D, O'Dorisio TM, Baum RP, Kulkarni HR, Caplin M, Lebtahi R, Hobday T, Delpassand E, Van Cutsem E, Benson A, Srirajaskanthan R, Pavel M, Mora J, Berlin J, Grande E, Reed N, Seregni E, Öberg K, Lopera Sierra M, Santoro P, Thevenet T, Erion JL, Ruszniewski P, Kwekkeboom D, Krenning E. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017 Jan.376(2):125-135. Pubmedid: 28076709. Pmcid: PMC5895095.
    • Luo G, Javed A, Strosberg JR, Jin K, Zhang Y, Liu C, Xu J, Soares K, Weiss MJ, Zheng L, Wolfgang CL, Cives M, Wong J, Wang W, Sun J, Shao C, Wang W, Tan H, Li J, Ni Q, Shen L, Chen M, He J, Chen J, Yu X. Modified Staging Classification for Pancreatic Neuroendocrine Tumors on the Basis of the American Joint Committee on Cancer and European Neuroendocrine Tumor Society Systems. J Clin Oncol. 2017 Jan.35(3):274-280. Pubmedid: 27646952.
    • Cives M, Strosberg J. Radionuclide Therapy for Neuroendocrine Tumors. Curr Oncol Rep. 2017 Feb.19(2):9. Pubmedid: 28220446.
    • Strosberg J, Krenning E. 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017 Apr.376(14):1391-1392. Pubmedid: 28379808.
    • Oberg K, Krenning E, Sundin A, Bodei L, Kidd M, Tesselaar M, Ambrosini V, Baum RP, Kulke M, Pavel M, Cwikla J, Drozdov I, Falconi M, Fazio N, Frilling A, Jensen R, Koopmans K, Korse T, Kwekkeboom D, Maecke H, Paganelli G, Salazar R, Severi S, Strosberg J, Prasad V, Scarpa A, Grossman A, Walenkamp A, Cives M, Virgolini I, Kjaer A, Modlin IM. A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management. Endocr Connect. 2016 Sep.5(5):174-187. Pubmedid: 27582247. Pmcid: PMC5045519.
    • Cives M, Ghayouri M, Morse B, Brelsford M, Black M, Rizzo A, Meeker A, Strosberg J. Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors. Endocr Relat Cancer. 2016 Sep.23(9):759-767. Pubmedid: 27552969.
    • Yao J, Fazio N, Buzzoni R, Delle Fave G, Tesselaar M, Wolin E, Van Cutsem E, Tomassetti P, Strosberg J, Voi M, Pacaud L, Ridolfi A, Singh S, Pavel M, Kulke M. ORAL02.02: Efficacy and Safety of Everolimus in Advanced, Progressive, Nonfunctional Neuroendocrine Tumors (NET) of the Lung: RADIANT-4 Subgroup Analysis: Topic: Medical Oncology. J Thorac Oncol. 2016 Nov.11(11S):S253. Pubmedid: 27969445.
    • Strosberg J, Cives M, Hwang J, Weber T, Nickerson M, Atreya C, Venook A, Kelley K, Valone T, Morse B, Coppola D, Bergsland E. A phase II study of axitinib in advanced neuroendocrine tumors. Endocr Relat Cancer. 2016 May.23(5):411-418. Pubmedid: 27080472. Pmcid: PMC4963225.
    • Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, Tomasek J, Raderer M, Lahner H, Voi M, Pacaud LB, Rouyrre N, Sachs C, Valle JW, Fave GD, Van Cutsem E, Tesselaar M, Shimada Y, Oh DY, Strosberg J, Kulke MH, Pavel ME. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016 Mar.387(10022):968-977. Pubmedid: 26703889. Pmcid: PMC6063317.
    • Strosberg J, Goldman J, Costa F, Pavel M. The Role of Chemotherapy in Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors. Front Horm Res. 2016 Jun.44:239-247. Pubmedid: 26303716.
    • Almhanna K, Weber J, Shridhar R, Hoffe S, Strosberg J, Meredith K. Determining the optimal number of lymph nodes harvested during esophagectomy. J Gastrointest Oncol. 2016 Jun.7(3):387-394. Pubmedid: 27284471. Pmcid: PMC4880760.
    • Cives M, Soares HP, Strosberg J. Will clinical heterogeneity of neuroendocrine tumors impact their management in the future? Lessons from recent trials. Curr Opin Oncol. 2016 Jul.28(4):359-366. Pubmedid: 27138571.
    • Mark J, Bush S, Glazer E, Strosberg J, Saglam O, Apte SM. Metastatic VIPoma presenting as an ovarian mass. Int J Surg Case Rep. 2016 Jan.17:167-169. Pubmedid: 26657531. Pmcid: PMC4701860.
    • Caldeira CC, Sayad D, Strosberg J, Faber C, Saouma S, Michaud T. Surgical Treatment of an Isolated Metastatic Myocardial Neuroendocrine Tumor. Ann Thorac Surg. 2016 Feb.101(2):747-749. Pubmedid: 26777929.
    • Kim R, Prithviraj GK, Shridhar R, Hoffe SE, Jiang K, Zhao X, Chen DT, Almhanna K, Strosberg J, Campos T, Shibata D. Phase I study of pre-operative continuous 5-FU and sorafenib with external radiation therapy in locally advanced rectal adenocarcinoma. Radiother Oncol. 2016 Feb.118(2):382-386. Pubmedid: 26861740. Pmcid: PMC7771531.
    • Srikumar T, Markow M, Centeno B, Hoffe S, Tao J, Fernandez H, Strosberg J, Shibata D. Synchronous rectal adenocarcinoma and splenic marginal zone lymphoma. Curr Oncol. 2016 Feb.23(1):e70-e74. Pubmedid: 26966416. Pmcid: PMC4754072.
    • Koumarianou A, Kaltsas G, Kulke MH, Oberg K, Strosberg JR, Spada F, Galdy S, Barberis M, Fumagalli C, Berruti A, Abdel-Rahman O, Fazio N. Temozolomide in Advanced Neuroendocrine Neoplasms: Pharmacological and Clinical Aspects. Neuroendocrinology. 2016 Apr.101(4):274-288. Pubmedid: 25924937.
    • Oberg K, Modlin IM, De Herder W, Pavel M, Klimstra D, Frilling A, Metz DC, Heaney A, Kwekkeboom D, Strosberg J, Meyer T, Moss SF, Washington K, Wolin E, Liu E, Goldenring J. Consensus on biomarkers for neuroendocrine tumour disease. Lancet Oncol. 2015 Sep.16(9):e435-e446. Pubmedid: 26370353. Pmcid: PMC5023063.
    • Abbott AM, Kim R, Hoffe SE, Arslan B, Biebel B, Choi J, El-Haddad G, Kis B, Sweeney J, Meredith KL, Almhanna K, Strosberg J, Shibata D, Fulp WJ, Shridhar R. Outcomes of Therasphere Radioembolization for Colorectal Metastases. Clin Colorectal Cancer. 2015 Sep.14(3):146-153. Pubmedid: 25795047.
    • Halfdanarson TR, Strosberg JR. Advances in Systemic Therapy for Gastroenteropancreatic Neuroendocrine Malignancies. Curr Clin Pharmacol. 2015 Nov.10(4):305-310. Pubmedid: 26548907.
    • Cives M, Strosberg J. The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors. Drugs. 2015 May.75(8):847-858. Pubmedid: 25911185.
    • Daud AI, Ashworth MT, Strosberg J, Goldman JW, Mendelson D, Springett G, Venook AP, Loechner S, Rosen LS, Shanahan F, Parry D, Shumway S, Grabowsky JA, Freshwater T, Sorge C, Kang SP, Isaacs R, Munster PN. Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors. J Clin Oncol. 2015 Mar.33(9):1060-1066. Pubmedid: 25605849.
    • Zhu J, Strosberg JR, Dropkin E, Strickler JH. Treatment of High-Grade Metastatic Pancreatic Neuroendocrine Carcinoma with FOLFIRINOX. J Gastrointest Cancer. 2015 Jun.46(2):166-169. Pubmedid: 25662891.
    • Morse B, Strosberg J. Congenital Anomaly Detected During Work-up of Cystic Pancreatic Lesion. Gastroenterology. 2015 Jul.149(1):33-34. Pubmedid: 26025308.
    • Kulke MH, Shah MH, Benson AB, Bergsland E, Berlin JD, Blaszkowsky LS, Emerson L, Engstrom PF, Fanta P, Giordano T, Goldner WS, Halfdanarson TR, Heslin MJ, Kandeel F, Kunz PL, Kuvshinoff BW, Lieu C, Moley JF, Munene G, Pillarisetty VG, Saltz L, Sosa JA, Strosberg JR, Vauthey JN, Wolfgang C, Yao JC, Burns J, Freedman-Cass D. Neuroendocrine tumors, version 1.2015. J Natl Compr Canc Ne. 2015 Jan.13(1):78-108. Pubmedid: 25583772.
    • Jones DH, Caracciolo JT, Hodul PJ, Strosberg JR, Coppola D, Bui MM. Familial gastrointestinal stromal tumor syndrome: report of 2 cases with KIT exon 11 mutation. Cancer Control. 2015 Jan.22(1):102-108. Pubmedid: 25504284.
    • Almhanna K, Hoffe S, Strosberg J, Dinwoodie W, Meredith K, Shridhar R. Concurrent chemoradiotherapy with protracted infusion of 5-fluorouracil (5-FU) and cisplatin for locally advanced resectable esophageal cancer. J Gastrointest Oncol. 2015 Feb.6(1):39-44. Pubmedid: 25642336. Pmcid: PMC4294830.
    • Broder MS, Beenhouwer D, Strosberg JR, Neary MP, Cherepanov D. Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: a systematic literature review. World J Gastroenterol. 2015 Feb.21(6):1945-1955. Pubmedid: 25684964. Pmcid: PMC4323475.
    • Cives M, Kunz P, Morse B, Schell MJ, Campos T, Nguyen PT, Nandoskar P, Khandelwal V, Strosberg J. Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors. Endocr Relat Cancer. 2015 Feb.22(1):1-9. Pubmedid: 25376618. Pmcid: PMC4643672.
    • Strosberg J, Yao JC, Bajetta E, Aout M, Bakker B, Hainsworth JD, Ruszniewski P, Van Cutsem E, Oberg KE, Pavel ME. Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis. Endocr Relat Cancer. 2015 Dec.22(6):933-940. Pubmedid: 26373569. Pmcid: PMC4609826.
    • Strosberg JR, Benson AB, Huynh L, Duh MS, Goldman J, Sahai V, Rademaker AW, Kulke MH. Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study. Oncologist. 2014 Sep.19(9):930-936. Pubmedid: 25096997. Pmcid: PMC4153451.
    • Sorbye H, Strosberg J, Baudin E, Klimstra DS, Yao JC. Gastroenteropancreatic high-grade neuroendocrine carcinoma. Cancer. 2014 Sep.120(18):2814-2823. Pubmedid: 24771552.
    • Cives M, Strosberg J. An update on gastroenteropancreatic neuroendocrine tumors. Oncology (Williston Park). 2014 Sep.28(9):749-56, 758. Pubmedid: 25224471.
    • Wong J, Fulp WJ, Strosberg JR, Kvols LK, Centeno BA, Hodul PJ. Predictors of lymph node metastases and impact on survival in resected pancreatic neuroendocrine tumors: a single-center experience. Am J Surg. 2014 Nov.208(5):775-780. Pubmedid: 24997491.
    • Strosberg JR. Systemic treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETS): current approaches and future options. Endocr Pract. 2014 Feb.20(2):167-175. Pubmedid: 24014009.
    • Saranga-Perry V, Morse B, Centeno B, Kvols L, Strosberg J. Treatment of metastatic neuroendocrine tumors of the thymus with capecitabine and temozolomide: a case series. Neuroendocrinology. 2014 Feb.97(4):318-321. Pubmedid: 23296364.
    • Strosberg J. Evolving treatment strategies for management of carcinoid tumors. CURR TREAT OPTION ON. 2013 Sep.14(3):374-388. Pubmedid: 23892588.
    • Kunz PL, Reidy-Lagunes D, Anthony LB, Bertino EM, Brendtro K, Chan JA, Chen H, Jensen RT, Kim MK, Klimstra DS, Kulke MH, Liu EH, Metz DC, Phan AT, Sippel RS, Strosberg JR, Yao JC. Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas. 2013 May.42(4):557-577. Pubmedid: 23591432. Pmcid: PMC4304762.
    • Strosberg J, Weber J, Feldman M, Goldman J, Almhanna K, Kvols L. Above-Label Doses of Octreotide-LAR in Patients With Metastatic Small Intestinal Carcinoid Tumors. Gastrointest Cancer Res. 2013 May.6(3):81-85. Pubmedid: 23936548. Pmcid: PMC3737510.
    • Casciano R, Wang X, Stern L, Parikh R, Chulikavit M, Willet J, Liu Z, Strosberg J, Cadiot G, Riechelmann R. International practice patterns and resource utilization in the treatment of neuroendocrine tumors. Pancreas. 2013 Mar.42(2):339-347. Pubmedid: 23357923.
    • Strosberg J, Chan J, Ryan DP, Meyerhardt JA, Fuchs CS, Abrams TA, Regan EM, Brady R, Weber J, Campos T, Kvols L, Kulke MH. A multi-institutional, phase II open-label study of ganitumab (AMG 479) in advanced carcinoid and pancreatic neuroendocrine tumors. Endocr Relat Cancer. 2013 Jun.20(3):383-390. Pubmedid: 23572164. Pmcid: PMC4029434.
    • Strosberg J. Advances in the Treatment of Pancreatic Neuroendocrine Tumors (pNETs). Gastrointest Cancer Res. 2013 Jul.6(4 Suppl 1):S10-S12. Pubmedid: 24312683. Pmcid: PMC3849907.
    • Strosberg JR. Update on the management of unusual neuroendocrine tumors: pheochromocytoma and paraganglioma, medullary thyroid cancer and adrenocortical carcinoma. Semin Oncol. 2013 Feb.40(1):120-133. Pubmedid: 23391119.
    • Strosberg JR, Weber JM, Feldman M, Coppola D, Meredith K, Kvols LK. Prognostic validity of the American Joint Committee on Cancer staging classification for midgut neuroendocrine tumors. J Clin Oncol. 2013 Feb.31(4):420-425. Pubmedid: 23248248.
    • Grozinsky-Glasberg S, Thomas D, Strosberg JR, Pape UF, Felder S, Tsolakis AV, Alexandraki KI, Fraenkel M, Saiegh L, Reissman P, Kaltsas G, Gross DJ. Metastatic type 1 gastric carcinoid: a real threat or just a myth?. World J Gastroenterol. 2013 Dec.19(46):8687-8695. Pubmedid: 24379587. Pmcid: PMC3870515.
    • Henderson-Jackson EB, Nasir A, Chen DT, Nandyala P, Djeu J, Strosberg J, Kvols L, Coppola D. Cytoplasmic Clusterin expression correlates with pancreatic neuroendocrine tumor size and pathological stage. Pancreas. 2013 Aug.42(6):967-970. Pubmedid: 23770713. Pmcid: PMC4644941.
    • Strosberg JR, Fisher GA, Benson AB, Malin JL, Cherepanov D, Broder MS. Systemic treatment in unresectable metastatic well-differentiated carcinoid tumors: consensus results from a modified delphi process. Pancreas. 2013 Apr.42(3):397-404. Pubmedid: 23211372.
    • Strosberg J, Casciano R, Stern L, Parikh R, Chulikavit M, Willet J, Liu Z, Wang X, Grzegorzewski KJ. United States-based practice patterns and resource utilization in advanced neuroendocrine tumor treatment. World J Gastroenterol. 2013 Apr.19(15):2348-2354. Pubmedid: 23613628. Pmcid: PMC3631986.
    • Strosberg JR, Weber JM, Choi J, Campos TL, Valone TL, Han G, Schell MJ, Kvols LK. A phase II clinical trial of sunitinib following hepatic transarterial embolization for metastatic neuroendocrine tumors. Ann Oncol. 2012 Sep.23(9):2335-2341. Pubmedid: 22317769. Pmcid: PMC4559904.
    • Cheema A, Weber J, Strosberg JR. Incidental detection of pancreatic neuroendocrine tumors: an analysis of incidence and outcomes. Ann Surg Oncol. 2012 Sep.19(9):2932-2936. Pubmedid: 22350605.
    • Almhanna K, Strosberg JR. Multimodality approach for locally advanced esophageal cancer. World J Gastroenterol. 2012 Oct.18(40):5679-5687. Pubmedid: 23155307. Pmcid: PMC3484335.
    • Naraev BG, Strosberg JR, Halfdanarson TR. Current status and perspectives of targeted therapy in well-differentiated neuroendocrine tumors. Oncology-Basel. 2012 Oct.83(3):117-127. Pubmedid: 22797357.
    • Dumont AG, Rink L, Godwin AK, Miettinen M, Joensuu H, Strosberg JR, Gronchi A, Corless CL, Goldstein D, Rubin BP, Maki RG, Lazar AJ, Lev D, Trent JC, von Mehren M. A nonrandom association of gastrointestinal stromal tumor (GIST) and desmoid tumor (deep fibromatosis): case series of 28 patients. Ann Oncol. 2012 May.23(5):1335-1340. Pubmedid: 21994214. Pmcid: PMC3493136.
    • Strosberg JR, Yeatman T, Weber J, Coppola D, Schell MJ, Han G, Almhanna K, Kim R, Valone T, Jump H, Sullivan D. A phase II study of RO4929097 in metastatic colorectal cancer. Eur J Cancer. 2012 May.48(7):997-1003. Pubmedid: 22445247. Pmcid: PMC4522922.
    • Kulke MH, Benson AB, Bergsland E, Berlin JD, Blaszkowsky LS, Choti MA, Clark OH, Doherty GM, Eason J, Emerson L, Engstrom PF, Goldner WS, Heslin MJ, Kandeel F, Kunz PL, Kuvshinoff BW, Moley JF, Pillarisetty VG, Saltz L, Schteingart DE, Shah MH, Shibata S, Strosberg JR, Vauthey JN, White R, Yao JC, Freedman-Cass DA, Dwyer MA. Neuroendocrine tumors. J Natl Compr Canc Ne. 2012 Jun.10(6):724-764. Pubmedid: 22679117.
    • Strosberg J. Neuroendocrine tumours of the small intestine. Best Pract Res Clin Gastroenterol. 2012 Dec.26(6):755-773. Pubmedid: 23582917.
    • Metz DC, Choi J, Strosberg J, Heaney AP, Howden CW, Klimstra D, Yao JC. A rationale for multidisciplinary care in treating neuroendocrine tumours. Curr Opin Endocrinol Diabetes Obes. 2012 Aug.19(4):306-313. Pubmedid: 22760514.
    • Strosberg JR, Cheema A, Weber JM, Ghayouri M, Han G, Hodul PJ, Kvols LK. Relapse-free survival in patients with nonmetastatic, surgically resected pancreatic neuroendocrine tumors: an analysis of the AJCC and ENETS staging classifications. Ann Surg. 2012 Aug.256(2):321-325. Pubmedid: 22415420.
    • Henderson-Jackson EB, Helm J, Strosberg J, Nasir NA, Yeatman TJ, Kvols LK, Coppola D, Nasir A. Palladin is a marker of liver metastasis in primary pancreatic endocrine carcinomas. Anticancer Res. 2011 Sep.31(9):2957-2962. Pubmedid: 21868544.
    • Nasir A, Helm J, Turner L, Chen DT, Strosberg J, Hafez N, Henderson-Jackson EB, Hodul P, Bui MM, Nasir NA, Hakam A, Malafa MP, Yeatman TJ, Coppola D, Kvols LK. RUNX1T1: a novel predictor of liver metastasis in primary pancreatic endocrine neoplasms. Pancreas. 2011 May.40(4):627-633. Pubmedid: 21499216. Pmcid: PMC4732279.
    • O'Neil BH, Goff LW, Kauh JS, Strosberg JR, Bekaii-Saab TS, Lee RM, Kazi A, Moore DT, Learoyd M, Lush RM, Sebti SM, Sullivan DM. Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma. J Clin Oncol. 2011 Jun.29(17):2350-2356. Pubmedid: 21519015. Pmcid: PMC3107750.
    • Strosberg JR, Fine RL, Choi J, Nasir A, Coppola D, Chen DT, Helm J, Kvols L. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer. 2011 Jan.117(2):268-275. Pubmedid: 20824724. Pmcid: PMC4665634.
    • Almhanna K, Strosberg J, Malafa M. Targeting AKT protein kinase in gastric cancer. Anticancer Res. 2011 Dec.31(12):4387-4392. Pubmedid: 22199303.
    • Strosberg JR, Cheema A, Weber J, Han G, Coppola D, Kvols LK. Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors. J Clin Oncol. 2011 Aug.29(22):3044-3049. Pubmedid: 21709192.
    • Strosberg JR, Cheema A, Kvols LK. A review of systemic and liver-directed therapies for metastatic neuroendocrine tumors of the gastroenteropancreatic tract. Cancer Control. 2011 Apr.18(2):127-137. Pubmedid: 21451455.
    • Strosberg J, Gardner N, Kvols L. Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid-gut. Neuroendocrinology. 2010 Mar.89(4):471-476. Pubmedid: 19174605.
    • Strosberg J, Kvols L. Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors. World J Gastroenterol. 2010 Jun.16(24):2963-2970. Pubmedid: 20572298. Pmcid: PMC2890935.
    • Barthel JS, Kucera ST, Lin JL, Hoffe SE, Strosberg JR, Ahmed I, Dilling TJ, Stevens CW. Does Barrett's esophagus respond to chemoradiation therapy for adenocarcinoma of the esophagus?. Gastrointest Endosc. 2010 Feb.71(2):235-240. Pubmedid: 20003971.
    • Ghayouri M, Boulware D, Nasir A, Strosberg J, Kvols L, Coppola D. Activation of the serine/theronine protein kinase Akt in enteropancreatic neuroendocrine tumors. Anticancer Res. 2010 Dec.30(12):5063-5067. Pubmedid: 21187491.
    • Anthony LB, Strosberg JR, Klimstra DS, Maples WJ, O'Dorisio TM, Warner RR, Wiseman GA, Benson AB, Pommier RF. The NANETS consensus guidelines for the diagnosis and management of gastrointestinal neuroendocrine tumors (nets): well-differentiated nets of the distal colon and rectum. Pancreas. 2010 Aug.39(6):767-774. Pubmedid: 20664474.
    • Phan AT, Oberg K, Choi J, Harrison LH, Hassan MM, Strosberg JR, Krenning EP, Kocha W, Woltering EA, Maples WJ. NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the thorax (includes lung and thymus). Pancreas. 2010 Aug.39(6):784-798. Pubmedid: 20664476.
    • Strosberg JR, Coppola D, Klimstra DS, Phan AT, Kulke MH, Wiseman GA, Kvols LK. The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas. Pancreas. 2010 Aug.39(6):799-800. Pubmedid: 20664477. Pmcid: PMC3100733.
    • Strosberg J, Nasir A, Coppola D, Wick M, Kvols L. Correlation between grade and prognosis in metastatic gastroenteropancreatic neuroendocrine tumors. Hum Pathol. 2009 Sep.40(9):1262-1268. Pubmedid: 19368957.
    • Strosberg JR, Hammer GD, Doherty GM. Management of adrenocortical carcinoma. J Natl Compr Canc Ne. 2009 Jul.7(7):752-758. Pubmedid: 19635227.
    • Clark OH, Benson AB, Berlin JD, Choti MA, Doherty GM, Engstrom PF, Gibbs JF, Heslin MJ, Kessinger A, Kulke MH, Kvols L, Salem R, Saltz L, Shah MH, Shibata S, Strosberg JR, Yao JC. NCCN Clinical Practice Guidelines in Oncology: neuroendocrine tumors. J Natl Compr Canc Ne. 2009 Jul.7(7):712-747. Pubmedid: 19635226.
    • Kvols LK, Turaga KK, Strosberg J, Choi J. Role of interventional radiology in the treatment of patients with neuroendocrine metastases in the liver. J Natl Compr Canc Ne. 2009 Jul.7(7):765-772. Pubmedid: 19635229.
    • Strosberg J, Gardner N, Kvols L. Survival and prognostic factor analysis in patients with metastatic pancreatic endocrine carcinomas. Pancreas. 2009 Apr.38(3):255-258. Pubmedid: 19066493.
    • Hodul P, Strosberg J, Kvols L. Aggressive surgical resection in the management of pancreatic neuroendocrine tumors: when is it indicated?. Cancer Control. 2008 Oct.15(4):314-321. Pubmedid: 18813199.
    • Strosberg JR, Nasir A, Hodul P, Kvols L. Biology and treatment of metastatic gastrointestinal neuroendocrine tumors. Gastrointest Cancer Res. 2008 May.2(3):113-125. Pubmedid: 19259290. Pmcid: PMC2633071.
    • Nasir A, Gardner N, Strosberg J, Ahmad N, Choi J, Malafa M, Coppola D, Kwekkeboom D, Teunissen J, Kvols L. Multimodality management of a polyfunctional pancreatic endocrine carcinoma with markedly elevated serum vasoactive intestinal polypeptide and calcitonin levels. Pancreas. 2008 Apr.36(3):309-313. Pubmedid: 18362846.
    • Strosberg J, Hoffe S, Gardner N, Choi J, Kvols L. Effective treatment of locally advanced endocrine tumors of the pancreas with chemoradiotherapy. Neuroendocrinology. 2007 Sep.85(4):216-220. Pubmedid: 17541257.
    • Strosberg J, Hoffe S, Hazelton T, Kvols L. External beam irradiation of myocardial carcinoid metastases: a case report. J Med Case Rep. 2007 Sep.1:95. Pubmedid: 17880715. Pmcid: PMC2040153.
    • Strosberg J, Nasir A, Cragun J, Gardner N, Kvols L. Metastatic carcinoid tumor to the ovary: a clinicopathologic analysis of seventeen cases. Gynecol Oncol. 2007 Jul.106(1):65-68. Pubmedid: 17475313.
    • Strosberg J, Kvols L. A review of the current clinical trials for gastroenteropancreatic neuroendocrine tumours. Expert Opin Inv Drug. 2007 Feb.16(2):219-224. Pubmedid: 17243941.
    • Strosberg JR, Shibata D, Kvols LK. Intermittent bowel obstruction due to a retained wireless capsule endoscope in a patient with a small bowel carcinoid tumour. Can J Gastroenterol. 2007 Feb.21(2):113-115. Pubmedid: 17299616. Pmcid: PMC2657671.
    • Strosberg J, Choi J, Cantor A, Kvols L. Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors. Cancer Control. 2006 Jan.13(1):72-78. Pubmedid: 16508629.
    • Nasir A, Stridsberg M, Strosberg J, Su P, Livingston S, Malik H, Kelley ST, Centeno B, Coppola D, Malafa M, Yeatman T, Kvols L. Somatostatin receptor profiling in hepatic metastases from small intestinal and pancreatic neuroendocrine neoplasms: immunohistochemical approach with potential clinical utility. Cancer Control. 2006 Jan.13(1):52-60. Pubmedid: 16508627.
    • Osborne D, Zervos E, Strosberg J, Boe B, Malafa M, Rosemurgy A, Yeatman TJ, Carey L, Duhaine L, Kvols L. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol. 2006 Apr.13(4):572-581. Pubmedid: 16511671.
    • Ambe CM, Nguyen P, Centeno BA, Choi J, Strosberg J, Kvols L, Hodul P, Hoffe S, Malafa MP. Multimodality Management of "Borderline Resectable" Pancreatic Neuroendocrine Tumors: Report of a Single-Institution Experience. Cancer Control. 24(5):1073274817729076. Pubmedid: 28975822. Pmcid: PMC5937248.
  • Patient Comments

    Overall Satisfaction


    188 patients rated this provider

    The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.

    Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

    Learn more about our patient satisfaction survey



    Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

    We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

    Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

    Learn more about our patient comments

    Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

    • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
    • He or she may be a researcher or other type of provider that does not see patients.
    • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.

    Learn more about our patient satisfaction survey, ratings and comments

Find a Doctor